the availability of clinical trials or other regulatory pathways, such as the Special Accessibility Plan, to request entry to the materialRequests through the Unique Access System need to deliver ample proof to guidance the usage of the drug with the patient's condition. Producers who offer medicine through the Exclusive Obtain Method are requested